Variable
|
Numbers of patients
|
Association with HOMA-IR
TRF & IP risk factor adjusted IR
β-Coefficient OR (95% CI)
#
|
---|
RF +ve *
|
90 (47%)
|
0.867 (0.204, 1.530)
|
ACPA +ve *
|
66 (35%)
|
1.423 (0.701, 2.146)
|
RF-ve/ACPA -ve
|
96 (49%)
|
0
|
RF +ve/
ACPA -ve †
|
29 (15%)
|
-0.015 (-0.973, 0.944)
|
ACPA+ve/
RF -ve†
|
6 (3%)
|
0.932 (-0.898, 2.763)
|
Both RF+ve/ACPA+ve †
|
60 (31%)
|
1.472 (0.695, 2.250)
√
|
- * = Seropositive vs. seronegative for RF and ACPA (n = 193 and 191, respectively)
- † = Patients stratified into four groups depending on autoantibody status and compared with other groups (n = 191)
- √ = Model significantly different in patients positive for both RF and ACPA relative to those RF positive only (P = 0.0061) with age and gender and other parameters adjusted.)
- ▲Linear regression producing β-coefficients were used for continuous outcome. β-coefficients are considered statistically significant if their 95% CI values do not include zero.
- #Logistic regression producing odds ratios used for binary outcomes. Odds ratios are considered significant if the 95% CI values do not include 1.
- ACPA, anti-CCP antibody; IP, inflammatory polyarthritis; RF, rheumatoid factor.